Global health update: September 3, 2026

• Researchers conducted a retrospective review of all novel FDA drug approvals from 2016 through 2024 to analyze the evidence used for authorization. • The study used FDA public records and the ClinicalTrials.gov database to track the number of completed trials and their funding sources.

• The Medicines and Healthcare products Regulatory Agency (MHRA) has suspended the new use of the drug avacopan after concluding that pivotal trial data is no longer reliable. • One pivotal clinical study underpinning the drug's license authorization was found to have compromised integrity and reliability.

• Government, industry, and public health sectors are collaborating to increase the adoption of common standards for clinical research data collection and sharing. • The initiative aims to prevent critical health findings from remaining hidden in fragmented data, ensuring that safety and efficacy results are transparent.

• New migraine prevention guidelines were released on Monday to help physicians navigate treatment options and secure insurance prior authorizations. • The updated framework emphasizes the integration of the newest prevention medications currently available on the market.

• 60 Degrees Pharmaceuticals will release a public presentation on September 11 regarding its medicines for vector-borne diseases. • Following the presentation, company management will meet with institutional investors in New York from September 14-16.

• Helus Pharma CEO Michael Halstead is scheduled to participate in a fireside chat during a conference on September 11. • The event will be webcast at 8 a.m. EDT, with a recording later made available on the company's investor relations website.

• The FDA has approved Oveporexton (brand name Orzeyful), developed by Takeda, for the treatment of narcolepsy type 1 in adults. • As the first drug to directly restore orexin signaling, the twice-daily tablet demonstrated improvements in daytime sleepiness, cataplexy, sleep paralysis, and hallucinations across two clinical trials.

• Updated COVID-19 vaccines are approved for the fall, with insurance coverage for the 2026-27 season depending on recommendations from the Advisory Committee on Immunization Practices (ACIP). • Under the Affordable Care Act, insurers must cover vaccines recommended by ACIP, but the panel has faced turmoil after HHS Secretary Robert F. Kennedy Jr. replaced all 17 members in June 2025.

• Researchers have developed a new hydrogel injection approach designed to keep osteoarthritis drugs effective within joints for several weeks. • The system utilizes a biocompatible polymer matrix and nanocarriers to act as a local reservoir, allowing for the delivery of hydrophobic therapeutic compounds.

• Leading U.S. medical groups issued updated guidelines on Wednesday urging the public to receive updated flu and COVID-19 vaccinations this fall. • The initiative aims to clear up public confusion regarding vaccination schedules and the science behind them, specifically addressing inconsistencies in previous administration advice.

• A recent Annenberg survey reveals a significant trust gap in U.S. healthcare, with 87% of Americans trusting their own doctors while confidence in the CDC, FDA, and NIH has dropped sharply. • This trend persists across various public health scenarios, including drug safety communications, food product recalls, and outbreak advisories.